Contardi et al. have reported that CTLA-4 can be constitutively expressed on several tumor cell lines with varying intensities and can trigger apoptosis of CTLA-4-expressing tumor cells after interaction with soluble CD80 (B7.1) or CD86 (B7.2) recombinant ligands [46,47]. Here, CD86 is linked to neoplasm.